Page last updated: 2024-12-07

cizolirtine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

cizolirtine: structure given in first source; analgesic with no ulcerogenic effects [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID132412
CHEMBL ID92501
SCHEMBL ID290138
MeSH IDM0353663

Synonyms (18)

Synonym
CHEMBL92501
cizolirtine
n,n-dimethyl-2-[(2-methylpyrazol-3-yl)-phenylmethoxy]ethanamine
cizolirtine [inn]
smp167wv5d ,
(+-)-5-(alph-(2-(dimethylamino)ethoxy)benzyl)-1-methylpyrazole.
142155-43-9
unii-smp167wv5d
(+-)-5-(alpha-(2-(dimethylamino)ethoxy)benzyl)-1-methylpyrazole
SCHEMBL290138
cizolirtine [mi]
(+/-)-5-(.alpha.-(2-(dimethylamino)ethoxy)benzyl)-1-methylpyrazole
cizolirtine [who-dd]
DCMJBKFKXGPPMT-UHFFFAOYSA-N
2-((1-methyl-1h-pyrazol-5-yl)(phenyl)methoxy)-n,n-dimethylethanamine
n,n-dimethyl-2-((1-methyl-1h-pyrazol-5-yl)(phenyl)methoxy)ethanamine
DTXSID10869923
Q27289287

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" There were 17 adverse events, of which five were possibly related to the study medication (one in the placebo group and four in the 150 mg E-4018 group)."( Dose response and safety of cizolirtine citrate (E-4018) in patients with pain following extraction of third molars.
Frame, JW; Matthew, IR; Ogden, GR; Wight, AJ, 2000
)
0.31
" A sample was composed of 135 outpatients with signs of lower urinary tract dysfunction and urodynamically documented detrusor overactivity; 20 patients left the study prematurely, chiefly (n=10) because of adverse events."( Cizolirtine citrate is safe and effective for treating urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study.
Abadías, M; Brod'ák, M; Pavlík, I; Schraml, P; Sust, M; Villoria, J; Vsetica, J; Zát'ura, F, 2010
)
0.36
" Adverse events were systematically recorded."( Cizolirtine citrate is safe and effective for treating urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study.
Abadías, M; Brod'ák, M; Pavlík, I; Schraml, P; Sust, M; Villoria, J; Vsetica, J; Zát'ura, F, 2010
)
0.36
" Cizolirtine citrate caused fewer antimuscarinic but more gastrointestinal (nausea) and neurologic (headache and vertigo) adverse events than oxybutynin."( Cizolirtine citrate is safe and effective for treating urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study.
Abadías, M; Brod'ák, M; Pavlík, I; Schraml, P; Sust, M; Villoria, J; Vsetica, J; Zát'ura, F, 2010
)
0.36
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (22)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (13.64)18.2507
2000's14 (63.64)29.6817
2010's3 (13.64)24.3611
2020's2 (9.09)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (22.73%)5.53%
Reviews1 (4.55%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other16 (72.73%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]